Unity focuses on the development of therapeutics that extend the human healthspan through intervention in the biological mechanisms associated with aging, thus enabling people to be healthier as they live longer. The Company’s initial emphasis is on “senolytics”—therapeutics that selectively eliminate senescent cells that accumulate with age. Unity’s first clinical programs are expected to include inflammatory joint diseases (osteoarthritis) and ophthalmology (glaucoma and age related macular degeneration).

(Nasdaq: UBX)